Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
On January 14, 2019, the Food and Drug Administration approved cabozantinib (CABOMETYX®, Exelixis, Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read more. 
ASCO recently published standards on the safe handling of hazardous drugs in the Journal of Clinical Oncology. ASCO’s standards largely endorse the practices recommended by other stakeholder groups for safely handling hazardous drugs but offer alternatives in areas where more research is needed to identify evidence-based safety measures.
Reimbursement cuts in certain oncology specialties. Consolidated payments for certain E&M services. Reduced reimbursement for new Medicare Part B drugs. These are some of the changes coming to the Medicare Physician Fee Schedule and the Quality Payment Program this year. In the latest ASCO in Action Podcast, ASCO CEO Dr. Clifford A. Hudis discusses these changes and what this may mean for your oncology practice.
Visit Cancer.NET, ASCO’s oncologist-approved patient information website, for a list of practice resources and ways that you can help ASCO share trusted cancer information with patients in multiple formats. Read more in English or in Spanish.
As part of the Trump Administration’s continuing effort to address the cost of prescription drugs, CMS recently solicited input on a proposed new pilot program to test mechanisms for reducing drug costs. The International Pricing Index Model (IPI) for Medicare Part B drugs proposes sweeping reforms that would, in part, benchmark some Medicare Part B drug prices against other countries and change how providers get paid for administering drugs to patients.